UCB (OTCMKTS:UCBJY) Shares Pass Below 50 Day Moving Average – What’s Next?

UCB SA (OTCMKTS:UCBJY)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $152.75 and traded as low as $142.53. UCB shares last traded at $144.61, with a volume of 57,166 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wolfe Research raised UCB to a “strong-buy” rating in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, UCB presently has an average rating of “Buy”.

UCB Price Performance

The business’s 50 day simple moving average is $152.75 and its 200 day simple moving average is $142.63. The company has a quick ratio of 1.01, a current ratio of 1.35 and a debt-to-equity ratio of 0.29.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.